scholarly journals Short-Term Outcomes in Treatment of Knee Osteoarthritis With 4 Bone Marrow Concentrate Injections

2018 ◽  
Vol 11 ◽  
pp. 117954411878108 ◽  
Author(s):  
Brent Shaw ◽  
Marc Darrow ◽  
Armen Derian
Keyword(s):  
Bone Marrow ◽  
Knee Osteoarthritis ◽  
Treatment Effectiveness ◽  
Short Term ◽  
Bone Marrow Concentrate ◽  
The Third ◽  
Promising Treatment ◽  
Preliminary Research ◽  
Larger Sample

Background: Preliminary research suggests that bone marrow concentrate (BMC), which contains mesenchymal stem cells and platelets, is a promising treatment for knee osteoarthritis. The aim of this study was to build on this preliminary research by reporting the short-term progress of 15 patients (20 knees) with knee osteoarthritis through 4 BMC treatments. Methods: Patients underwent four sequential BMC treatments with mean injection times of 13.80 days after the first treatment, 21.40 days after the second treatment, and 33.50 days after the third treatment. The last follow-up was conducted a mean 86 days after the first treatment. Baseline and posttreatment outcomes of resting pain, active pain, lower functionality scale, and overall improvement percentage were compared after each treatment. Results: Patients experienced statistically significant improvements in active pain and functionality score after the first treatment. Additionally, patients experienced a mean decrease in resting pain after the first treatment, yet outcomes were not statistically significant until after the second treatment. On average, patients experienced an 84.31% decrease in resting pain, a 61.95% decrease in active pain, and a 55.68% increase in functionality score at the final follow-up. Patients also reported a mean 67% total overall improvement at study conclusion. Outcomes at the final follow-up after the fourth treatment were statistically significant compared to outcomes at baseline, after first treatment, after second treatment, and after third treatment. Conclusions: These results are promising, and additional research with a larger sample size and longer follow-up is needed to further examine the treatment effectiveness of multiple BMC injections for knee osteoarthritis.

scholarly journals Short-Term Outcomes of Treatment of Hip Osteoarthritis With 4 Bone Marrow Concentrate Injections: A Case Series

2018 ◽  
Vol 11 ◽  
pp. 117954761879157 ◽  
Author(s):  
Marc Darrow ◽  
Brent Shaw ◽  
Brittany Darrow ◽  
Stevie Wisz
Keyword(s):  
Bone Marrow ◽  
Total Joint Replacement ◽  
Case Series ◽  
Hip Osteoarthritis ◽  
Daily Activities ◽  
Limited Evidence ◽  
Short Term ◽  
Bone Marrow Concentrate

The use of mesenchymal stem cells from bone marrow concentrate (BMC) has become an increasingly popular option as an alternative to total joint replacement. Although there is evidence to support the use of BMC injections to improve quality of life for patients with knee osteoarthritis (OA), there is limited evidence to support its use in patients with hip OA. This case series provides the short-term outcomes of 4 hip OA patients who each underwent 4 BMC injections. On average, the last follow-up was administered 3.5 months after the first injection. The results show that patients experienced decreased resting and active pain compared with baseline and mean 72.4% total overall improvement. Patients also reported less difficulty in performing daily activities following the procedure. These encouraging results warrant further research to better understand the effects of BMC injections on hip OA.

scholarly journals Efficacy of Surgery Combined with Autologous Bone Marrow Stromal Cell Transplantation for Treatment of Intracerebral Hemorrhage

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Jianxin Zhu ◽  
Yilei Xiao ◽  
Zhongmin Li ◽  
Fabin Han ◽  
Taiwu Xiao ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Barthel Index ◽  
Autologous Bone Marrow ◽  
Control Group ◽  
Short Term ◽  
System Disease ◽  
Therapeutic Benefits ◽  
Neurologic Impairment ◽  
Significant Difference

Bone marrow stromal cells (BMSCs) may differentiate into nerve cells under a certain condition; however, the clinical application for treating nervous system disease remains unclear. The aim is to assess the safety profile, feasibility, and effectiveness of surgery combined with autologous BMSCs transplantation for treating ICH. 206 ICH patients who had received surgical procedure were divided into transplantation (n=110) or control group (n=96). For transplantation group, BMSCs were injected into the perihemorrhage area in the base ganglia through an intracranial drainage tube 5.5 (3.01–6.89) days after surgery, followed by a second injection into the subarachnoid space through lumbar puncture 4 weeks later. Neurologic impairment and daily activities were assessed with National Institute Stroke Scale (NIHSS), Barthel index, and Rankin scale before transplantation and 6 months and 12 months after transplantation. Our results revealed that, compared with control group, NIHSS score and Rankin scale were both significantly decreased but Barthel index was increased in transplantation group after 6 months. Interestingly, no significant difference was observed between 12 months and 6 months. No transplantation-related adverse effects were investigated during follow-up assessments. Our findings suggest that surgery combined with autologous BMSCs transplantation is safe for treatment of ICH, providing short-term therapeutic benefits.

scholarly journals Short-Term Outcomes of the Subchondroplasty Procedure for the Treatment of Bone Marrow Edema Lesions in Patients with Knee Osteoarthritis

2015 ◽  
Vol 3 (7_suppl2) ◽  
pp. 2325967115S0012 ◽  
Author(s):  
Adrian Thomas Davis ◽  
Jennifer Marie Byrd ◽  
Justin Angelo Zenner ◽  
Darren A. Frank ◽  
Patrick J. DeMeo ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Knee Osteoarthritis ◽  
Bone Marrow Edema ◽  
Short Term ◽  
Marrow Edema

scholarly journals Intra-articular bone marrow concentrate injection protocol: short-term efficacy in osteoarthritis

2016 ◽  
Vol 11 (6) ◽  
pp. 511-520 ◽  
Author(s):  
Steven Sampson ◽  
Jay Smith ◽  
Hunter Vincent ◽  
Danielle Aufiero ◽  
Mona Zall ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Short Term ◽  
Bone Marrow Concentrate ◽  
Term Efficacy ◽  
Injection Protocol

scholarly journals Efficacy of Autologous Bone Marrow Concentrate for Knee Osteoarthritis with and without Adipose Graft

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Christopher Centeno ◽  
John Pitts ◽  
Hasan Al-Sayegh ◽  
Michael Freeman
Keyword(s):  
Bone Marrow ◽  
Knee Osteoarthritis ◽  
Autologous Bone Marrow ◽  
Pain Scale ◽  
Bone Marrow Concentrate ◽  
Knee Oa ◽  
Percentage Improvement ◽  
Treatment Type ◽  
The Mean ◽  
Autologous Bone

Introduction.We investigated the use of autologous bone marrow concentrate (BMC) with and without an adipose graft, for treatment of knee osteoarthritis (OA).Methods.Treatment registry data for patients who underwent BMC procedures with and without an adipose graft were analyzed. Pre- and posttreatment outcomes of interest included the lower extremity functional scale (LEFS), the numerical pain scale (NPS), and a subjective percentage improvement rating. Multivariate analyses were performed to examine the effects of treatment type adjusting for potential confounding factors. The frequency and type of adverse events (AE) were also examined.Results.840 procedures were performed, 616 without and 224 with adipose graft. The mean LEFS score increased by 7.9 and 9.8 in the two groups (out of 80), respectively, and the mean NPS score decreased from 4 to 2.6 and from 4.3 to 3 in the two groups, respectively. AE rates were 6% and 8.9% in the two groups, respectively. Although pre- and posttreatment improvements were statistically significant, the differences between the groups were not.Conclusion.BMC injections for knee OA showed encouraging outcomes and a low rate of AEs. Addition of an adipose graft to the BMC did not provide a detectible benefit over BMC alone.

scholarly journals Phase II Multicenter Randomized Controlled Clinical Trial on the Efficacy of Intra-articular Injection of Autologous Bone Marrow Mesenchymal Stem Cells with Platelet Rich Plasma for the Treatment of Knee Osteoarthritis

2020 ◽  
Author(s):  
José María Lamo-Espinosa ◽  
Juan F. Blanco ◽  
Mikel Sánchez ◽  
Victoria Moreno ◽  
Froilán Granero-Moltó ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bone Marrow ◽  
Clinical Trials ◽  
Knee Osteoarthritis ◽  
Phase Ii ◽  
Stromal Cells ◽  
Platelet Rich Plasma ◽  
X Ray ◽  
The Mean

Abstract Background: Mesenchymal stromal cells are a safe and promising option to treat knee osteoarthritis as previously demonstrated in different clinical trials. However, their efficacy, optimal dose and addition of adjuvants must be determined. Here, we evaluated the clinical effects of a dose of 100x106 bone marrow mesenchymal stromal cells (BM-MSCs) in combination with Platelet Rich Plasma (PRGF®) as adjuvant in a randomized clinical trial.Methods: A phase II, multicenter, randomized clinical trial with active control was conducted. Sixty patients diagnosed with knee OA were randomly assigned to 3 weekly doses of PRGF® or intraarticular administration of 100x106 cultured autologous BM-MSCs plus PRGF®. Patients were followed up for 12 months, and pain and function were assessed using VAS and WOMAC and by measuring the knee range of motion range. X-ray and magnetic resonance imaging analyses were performed to analyze joint damage.Results: No adverse effects were reported after BM-MSC administration or during follow-up. According to VAS, the mean value (SD) for PRGF® and BM-MSC with PRGF® went from 5 (1.8) to 4.5 (2.2) (p=0.389) and from 5.3 (1.9) to 3.5 (2.5) (p=0.01), respectively at 12 months.. In WOMAC, the mean (SD) baseline and 12-month overall WOMAC scores in patients treated with PRGF® was 31.9 (16.2) and 22.3 (15.8) respectively (p=0.002) while that for patients treated with BM-MSC plus PRGF® was 33.4 (18.7) and 23.0 (16.6) (p=0.053). Although statistical significances between groups have been not detected, only patients being treated with BM-MSC plus PRGF® could be considered as a OA treatment responders following OARSI criteria. X-ray and MRI (WORMS protocol) revealed no changes in knee joint space width or joint damage.Conclusions: Treatment with BM-MSC associated with PRGF® was shown to be a viable therapeutic option for osteoarthritis of the knee, with clinical improvement at the end of follow-up. Further phase III clinical trials would be necessary to confirm the efficacy. Clinical Trials.gov identifier NCT02365142. Nº EudraCT: 2011-006036-23

scholarly journals New Modalities in Knee Osteoarthritis Treatment Using Autologous Bone Marrow-Derived Mononuclear Cells

2018 ◽  
Vol 72 (4) ◽  
pp. 207-215
Author(s):  
Valdis Gončars ◽  
Konstantīns Kalnbērzs ◽  
Ēriks Jākobsons ◽  
Ieva Briede ◽  
Kristaps Blūms ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Bone Marrow ◽  
Magnetic Resonance ◽  
Knee Osteoarthritis ◽  
Mononuclear Cell ◽  
Mononuclear Cells ◽  
Intraarticular Injection ◽  
Control Group ◽  
Resonance Imaging

Abstract The clinical effects on knee osteoarthritis (OA) symptoms and tissue structure were evaluated after bone marrow-derived mononuclear cell intraarticular injection. A group of 32 patients with 34 knee joints in stage II–III osteoarthritis were treated by intraarticular injection of mononuclear cell suspension. Clinical results were obtained by KOOS (Knee Osteoarthritis Outcome Score) and KSS (Knee Society Score) scores during a 12 months follow-up period. Radiological evaluation was performed using magnetic resonance imaging. A comparison with a control group of 28 patients treated with routinely used three hyaluronic acid intra-articular injections was made. No adverse effects were observed after the bone marrow derived mononuclear cells (BM-MNC) injection. At the end point of the follow up all score results had improved, compared to those at to the starting point. 65% of patients maintained minimal perceptible clinical improvement of the score results. The Whole Organ Magnetic Resonance Imaging Score showed improvement from 44.31 to 42.93 points (p < 0.05) during a 6–7 month period. Comparing score results to the control group, a statistically significant (p < 0.05) improvement in the KOOS pain subscale score at the 6 and 12 months was observed in the mononuclear cell group. BM-MNC injection leads to a decrease of knee OA symptoms and slows changes in structure of the degenerative joint tissue.

Sign in / Sign up

Export Citation Format

Share Document